COMMUNIQUÉS West-GlobeNewswire

RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview
23/06/2026
New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx , a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing [...]
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support
23/06/2026
New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- Zealthy announced today the launch of its enhanced virtual weight-loss care platform, designed to simplify access to provider-guided obesity treatment through integrated [...]
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
23/06/2026
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc [...]
AM Rx Announces Expanded Online Access and Insurance Support for Zepbound
23/06/2026
Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care New York, NY, June 23, 2026 (GLOBE [...]
Asimov Launches Chrysalis Transposase, a Wholly-Owned Genome Integration Tool for Biotherapeutics Production
23/06/2026
Engineered from the genomes of multiple butterfly species, Chrysalis transposase achieves fast cell recovery, stable expression over 60 cellular generations, and high expression across transgenes. In recent customer [...]
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06/2026
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high - [...]
GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités
23/06/2026
Le médicament expérimental GNS561 a démontré un profil de sécurité et de tolérabilité favorable dans une étude de Phase 1b évaluant son potentiel en combinaison avec un inhibiteur de MEK (MEKi) Étude menée dans une [...]
RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026
MIAMI, June 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
SK pharmteco lance SKyvec™, une plateforme unifiée de vecteurs viraux à haut rendement destinée à accélérer le développement des thérapies géniques, de la fabrication au patient
23/06/2026
RANCHO CORDOVA, Californie, 23 juin 2026 (GLOBE NEWSWIRE) -- SK pharmteco annonce ce jour le lancement de SKyvec™, sa plateforme exclusive et multimodale de vecteurs viraux. Conçue pour soutenir les programmes de [...]
Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
23/06/2026
Data presented at the American Transplant Congress 2026 reports transvenous phrenic nerve stimulation reduced lung collapse and significantly increased availability of lungs that meet transplant criteria versus [...]
Berry Street and Tia Partner to Deliver Clinical Nutrition Therapy at Every Stage of a Woman's Life
23/06/2026
Tia members gain access to Berry Street's AI-powered platform and network of 1,800+ Registered Dietitians specializing in women's health NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Berry Street , the leading metabolic [...]
X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy
23/06/2026
GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward supports advancement of X- [...]
Peptide Mind Launches Expanded Research Library and Educational Tools for Peptide Research Community
23/06/2026
New platform resources provide structured, citation-backed peptide education and research tools for students, researchers, and science-minded readers. Official logo of the Peptide Mind research and education platform. [...]
EssilorLuxottica et Meta étendent l’accès à la catégorie des wearables avec une nouvelle collection
23/06/2026
EssilorLuxottica et Meta étendent l’accès à la catégorie des wearables avec une nouvelle collection Fortes d’un portefeuille de lunettes IA faisant référence, les deux entreprises visent à apporter l'innovation des [...]
Sigmatic Sciences Powers AI Scientists with NVIDIA’s Latest BioNeMo Agentic Capabilities
23/06/2026
The First Agentic Operating System for Life Sciences R&D PRESS RELEASE Already running NVIDIA BioNeMo in production, the SigmaticOS now leverages NVIDIA’s latest agentic innovations to connect AI agents, scientific [...]
EssilorLuxottica and Meta expand the accessibility of wearables category with new collection
23/06/2026
EssilorLuxottica and Meta expand the accessibility of wearables category with new collection Building on their market-leading portfolio of AI glasses, the two companies aim to introduce more consumers to smart eyewear [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
23/06/2026
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]

Pages